Multiple myeloma presenting as cutaneous leukocytoclastic vasculitis and eosinophilia disclosing a T helper type 1/T helper type 2 imbalance: a case report.

Authors:
Satoko Oka
Satoko Oka
Osaka Medical College
Japan
Kazuo Ono
Kazuo Ono
Fukushima Medical University
Japan
Masaharu Nohgawa
Masaharu Nohgawa
Wakayama Medical Center
Wakayama | Japan

J Med Case Rep 2018 Oct 31;12(1):320. Epub 2018 Oct 31.

Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.

Background: Multiple myeloma is a very heterogeneous disease comprising a number of genetic entities that differ from each other in their evolution, mode of presentation, response to therapy, and prognosis. Due to its more chronic nature and cumulative toxicities that patients develop from multiple lines of treatments, a number of symptoms are associated with multiple myeloma. However, the mechanisms responsible for the relationship between these symptoms and multiple myeloma currently remain unclear.

Case Presentation: An 85-year-old Japanese woman exhibited the rare presentation of multiple myeloma (immunoglobulin kappa chain type) with leukocytoclastic vasculitis and eosinophilia. The serum level of interferon-γ was decreased; however, serum levels of interleukin-4, interleukin-5, interleukin-6, interleukin-10, and tumor growth factor-β levels were elevated. She received a bortezomib, lenalidomide, and dexamethasone regimen. After one course of the treatment, the cutaneous manifestation rapidly improved and laboratory tests showed decrease of eosinophil cell count. Serum concentrations of immunoglobulin G decreased and plasma cells in bone marrow decreased. The serum level of interferon-γ was elevated and serum levels of interleukin-4, interleukin-5, interleukin-6, interleukin-10, and tumor growth factor-β decreased.

Conclusions: It is the first case of leukocytoclastic vasculitis and eosinophilia in multiple myeloma that was associated with a T helper type 1/T helper type 2 imbalance and T regulatory cells, and was successfully treated with bortezomib, lenalidomide, and dexamethasone. The present case reinforces the value of early evaluations for paraneoplastic symptoms in order to reach a diagnosis and allow for the prompt initiation of appropriate treatments and achieve successful therapeutic management.

Download full-text PDF

Source
https://jmedicalcasereports.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13256-018-1857-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208011PMC
October 2018
13 Reads

Publication Analysis

Top Keywords

multiple myeloma
24
helper type
16
vasculitis eosinophilia
12
leukocytoclastic vasculitis
12
decreased serum
8
serum levels
8
level interferon-γ
8
type imbalance
8
1/t helper
8
lenalidomide dexamethasone
8
levels interleukin-4
8
bortezomib lenalidomide
8
interleukin-10 tumor
8
tumor growth
8
interleukin-6 interleukin-10
8
interleukin-5 interleukin-6
8
interleukin-4 interleukin-5
8
type 1/t
8
growth factor-β
8
serum level
8

References

(Supplied by CrossRef)
Article in J Am Acad Dermatol
HC Nousari et al.
J Am Acad Dermatol 2000
Article in Clin Exp Dermatol
IB Bayer-Garner et al.
Clin Exp Dermatol 2003
Article in J Eur Acad Dermatol Venereol
NB Sánchez et al.
J Eur Acad Dermatol Venereol 2004
Article in Arthritis Rheum
C García-Porrúa et al.
Arthritis Rheum 1998
Article in Dermatol Ther
G Buggiani et al.
Dermatol Ther 2010
Article in Blood
B Klein et al.
Blood 1989
Article in N Engl J Med
R Bataille et al.
N Engl J Med 1997
Article in Am J Clin Pathol
L Glantz et al.
Am J Clin Pathol 1995
Article in Blood
M Ostad et al.
Blood 2008
Article in Cancer Immunol Immunother
S Hong et al.
Cancer Immunol Immunother 2012

PJ Lynch et al.
1988

Similar Publications